glutathione cancer studies responsive nanomedicine leverages tumor redox imbalance for targeted theranostics | Discover Oncology Glutathione-mediated nanomedicines for cancer diagnosis
Description
doi:10.2174/157015913666160502153022 Sikiric P, Blagaic AB, Strbe S, et al
REDEFINE 4 an 84-week head-to-head efficacy and safety phase 3 trial of once-weekly CagriSema versus once-weekly tirzepatide
doi: 10.3390/healthcare6010016 9 MaloneyEL
Across all of it, he keeps returning to one frame: peptides are amino acid sequences the body recognises, not drugs in the conventional sense
